Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The RECAP 2 Study
NCT06692192Phase 1Recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Aug 2025
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised trial of psilocybin (4 arms), sponsored by University of Wisconsin–Madison. Primary endpoints: Warwick-Edinburgh Mental wellbeing Scale at 7 days, Brief Experiential Avoidance Questionnaire at 7 days and 2 more. Started Aug 2025; status: recruiting.
02
Drugs
psilocybin
Beyond the preview
Go deeper on NCT06692192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06692192.